# A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents

> **NCT00915655** · PHASE2 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 12 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** darunavir
- **DRUG:** ritonavir
- **DRUG:** zidovudine
- **DRUG:** lamivudine
- **DRUG:** abacavir

## Key facts

- **NCT ID:** NCT00915655
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2010-09
- **Final completion:** 2011-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2012-09-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00915655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00915655, "A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00915655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*